V12 SENTINEL ENGINE · AI MARKET ANALYSIS
Mid
R
RVMDAI Stock Diagnostic Report

Revolution Medicines updates 2026 GAAP operating expenses to $2.1B-$2.2B while preparing potential daraxonrasib launch

Revolution Medicines announced that it expects to reach a turning point in 2026 through significant results from RASolute 302 and an expanded FDA approval program.

View Source Article ↗
AI CATALYST SCORE78 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+
ANALYSIS HISTORY

RVMD Analysis History (Last 30 Days)

Diagnosed AtTickerAI ScoreTier
2026-08-26 15:03:35RVMD90S-ClassView Report →
2026-08-05 23:04:25RVMD78MidView Report →
2026-07-06 12:57:20RVMD85MidView Report →
View Full History for RVMD (Blueprint) →